Zhong, Zhenyu
Liang, Shuang
Sanchez-Lopez, Elsa
He, Feng
Shalapour, Shabnam
Lin, Xue-jia
Wong, Jerry
Ding, Siyuan
Seki, Ekihiro
Schnabl, Bernd
Hevener, Andrea L.
Greenberg, Harry B.
Kisseleva, Tatiana
Karin, Michael
Article History
Received: 4 August 2017
Accepted: 13 June 2018
First Online: 25 July 2018
Competing interests
: The University of California San Diego is in the process of applying for a patent application (US Provisional Application Serial no. 62/690,175) covering the use of IRF1 and/or CMPK2 genetic/chemical inhibitors to treat NLRP3 inflammasome-associated diseases that lists Z.Z. and M.K. as inventors.